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Summary 
BALB/c radiation leukemia RLCel is an immunogenic tumor. We established bulk and cloned 
cytotoxic T  lymphocyte (CTL) lines from regressor (BALB/c  x  C57BL/6)F1  (CB6F 0  spleen 
cells that recognized ILLo'I specifically. We then obtained antigen peptide recognized by CTL 
from ILLcYl by acid extraction. Analysis of the acid extract by reversed-phase high performance 
liquid chromatography (HPLC) on a semipreparative C18 column revealed that fractions eluted 
in 23 min (peak a) and 26 min (peak b) showed sensitization activity on the P815  target for 
specific CTL. On further purification of these fractions by HPLC and direct sequencing by Edman 
degradation, we identified the CTL-recognizing RLO'I peptide piLLla (IPGLPLSL) in peak a 
and its possible precursor peptide pRLlb (SIIPGLPLSL)  in peak b. Sequence homology indicated 
that  these peptides were derived from the 5' untranslated region of c-akt oncogene. 
T 
umor rejection antigens were first found on methyl- 
cholanthrene-induced fibrosarcomas in mice (1-5). Im- 
munization of syngeneic mice with a tumor was shown to 
render these mice resistant to successive challenge by the same 
tumor. A characteristic of tumor rejection antigens is extremely 
high polymorphism. In fact, even two tumors in the same 
animal possess  different rejection antigens (6).  These indi- 
vidually distinct antigens were later found on a variety of 
tumors of many other histological types in different species. 
Studies on adoptive transfer showed that the tumor rejec- 
tion response is mediated by T  cells (7,  8);  CD8 + T  cells 
are predominantly responsible for rejection, whereas CD4 + 
T cells are involved to various extents depending on the tumor. 
It  is  generally accepted that  the effector cells  are mainly 
CD8 +  CTL  and  that  CD4 +  T  cells  help  CD8 +  CTL 
precursors to differentiate into effector cells (9, 10). In cases 
not involving CD4 + T cells, CD8 + helper cells participate 
in CTL induction (10). 
BALB/c radiation-induced leukemia RLo'I is a highly im- 
munogenic tumor. In BALB/c mice hybridized with certain 
mouse strains,  inocula of ILLO'I cells initially grew, formed 
a tumor, and then regressed. The different immune respon- 
sivenesses to RLcYl rejection antigen of the various mouse 
strains used for producing F1 hybrids have been ascribed to 
a gene located in the H-2K region (11). Spleen cells from 
regressor (BALB/c  x  C57BL/6)F1  (CB6F1) 1 mice generate 
CD8 + CTL after in vitro stimulation (12). CTL have been 
shown  to  recognize RLCYl, but  not  other  ILL  series  of 
leukemias, radiation-leukemia virus-induced leukemias, fibro- 
sarcomas, or blasts from normal lymphoid cells. These findings 
suggest that there is a unique (individually distinct) antigen 
on RLcYl. Adoptive transfer of CTL to BALB/c nu/nu mice 
protected the recipient mice from subsequent challenge with 
RLo'I  cells  (13).  In  vivo  depletion  of  CD8 +  T  cells 
abrogated the rejection, whereas depletion of CD4 + T cells 
had little effect (14, 15). These findings suggest that the RLo'I 
rejection response is mediated by CD8 + CTL. In this study, 
we identified a unique rejection antigen peptide, pILL1, that 
is recognized on RLCYl by CTL derived from semisyngeneic 
CB6F1  mice.  Sequence  homology  analysis  revealed  that 
pILL1  is derived from the 5'  untranslated region of c-akt 
oncogene (16). 
Materials  and Methods 
Mice.  BALB/c, C57BL/6  (B6), and CB6F1 mice were pur- 
chased from Japan SLC Co. (Shizuoka, Japan). Breeding pairs of 
1 Abbreviations used in this paper: CB6F1, (BALB/c x  C57BL/6)F1; r, 
recombinant. 
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sity Medical School, Osaka, Japan). These mice were bred in our 
animal center. 
Tumors and Cell Lines.  RLCel, RLCY4, and RL98 are radiation- 
induced leukemias in BALB/c mice (12).  RVA, RVC,  and RVD 
are leukemias induced by injection of radiation leukemia virus into 
neonatal BALB/c mice (17). P815 is a methylcholanthrene-induced 
mastocytoma in a DBA/2 mouse (18). These tumors were main- 
tained in the strain of origin. T1.1.1 and T4.8.3 are derivatives of 
L cells (H-2  ~) transfected  with the H-2L  a and H-2D  d gene, respec- 
tively (19),  and were provided by Dr.  N. Shinohara  (Mitsubishi 
Kasei Institute of Life Science,  Machida, Japan). 
Antibodies.  Anti-L3T4 (CD4) mAb, a rat antibody of the IgG2b 
immunoglobulin class, produced by hybridoma GK1.5 (20),  was 
provided by Dr. F. Fitch (University of Chicago, Chicago, IL). Anti- 
Lyt-2.2 (CDS) mAb, a mouse antibody of the IgG2a class, pro- 
duced by hybridoma 19/178 was provided by Dr. U. H~immerling 
(Memorial Sloan-Kettering  Cancer Center, New York). Anti-TCR-j8 
mAb, a hamster antibody of the IgG class, produced by hybridoma 
H57-597 (21) was provided by Dr. R. Kubo (National Jewish Center, 
Denver, CO).  Anti-CD3e  mAb, a hamster antibody of the IgG 
class, produced by hybridoma 145-2Cll (22), was provided by Dr. 
J. A. Bluestone (University of Chicago). Anti-H-2K  d and anti-H- 
2D d mAbs are mouse antibodies of the IgG2a class produced by 
hybridomas KD40 and DD98, respectively, that were established 
by hybridization of P3U1 myeloma and spleen cells from BALB.B 
mice that had been immunized with BALB/c lymphoid cells. Anti- 
H-2L  a mAb is a mouse IgG2a antibody produced by a hybridoma 
30-5-7  (23).  Anti-lA d mAb is a mouse IgG2b antibody produced 
by hybridoma MK-D6 (24). Anti-IE  k,a mAb is a mouse IgG2b an- 
tibody produced by hybridoma ISCR3 (25).  These mAbs were 
provided by Dr.  N.  Shinohara. 
Peptide Synthesis and Purification.  Peptides  were synthesized by 
standard solid-phase methods using Fmoc chemistry in a Peptide 
synthesizer (model 430A; Applied Biosystems, Foster City, CA). 
Cleavage of the peptide from the resin and removal of the side chain 
protecting groups were carried out using 95% trifluoroacetic acid 
(TFA).  The  peptides  were  purified  to  >98%  homogeneity by 
reversed-phase  HPLC on a preparative C8 column (10 x  100 mm, 
20/ira  particle size; Applied Biosystems) in 0.1%  TFA with an 
acetonitrile gradient. The purity ofpeptides was assayed in an ana- 
lytical C18 column (4.6  x  150 mm, 5 #m particle size; Chemco, 
Osaka, Japan). The integrity of the purified Peptides was confirmed 
by fast atom bombardment mass spectrometry (model 9020-DF; 
Shimazu,  Kyoto, Japan). 
Sequence Analysis.  Sequencing  was Performed by NH2-terminal 
Edman degradation using a protein sequencer (model 477A; Ap- 
plied Biosystems, Inc.) coupled to a phenyl thiohydantoin analyzer 
(model 120A; Applied Biosystems, Inc.). Amino acid sequence ho- 
mology was investigated using the National Biomedical Research 
Foundation  (NBRF)  database using GENETYX-MAC  (Genetic 
Bio Database Software, Software Development Co., Tokyo, Japan). 
Acid Extraction of Whole Cells and HPLC Analysis.  Samples of 
2.5  x  1011 RLcYl ascites cells from 250 BALB/c mice were homo- 
genized by 10 strokes in 0.1% TFA with a Dounce homogenizer 
and sonicated (Sonifier W-185; Branson Sonic Power, Danbury, CT) 
for 3 min. The homogenates were then stirred at pH 2.0 in 0.1% 
TFA for 30 rain. The supernatants obtained by centrifugation at 
100,000 g for 30 min were filtered with a molecular cut-off mem- 
brane (m.w. 5000,  PLCC; Millipore Corp., Bedford, MA). These 
procedures were clone at 4~  The filtrates obtained from 10 mice 
were lyophilized, resolved in 0.1% TFA, and analyzed by reversed- 
phase HPLC (model 625L; Waters/Millipore, Milford, MA) on a 
semipreparative C18 column (ODP, 10  x  250 ram, 10/~m parti- 
cles; Asahipak, Kawasaki, Japan). Solvent A was 0.1%  TFA and 
solvent B was acetonitrile containing 0.1% TFA. The gradient for 
chromatography was 20-60% B over 40 min. The fractions (2.0 
ml) collected at 1 min intervals were assayed for sensitization ac- 
tivity on P815  cells for anti-RLcYl CTL (see below).  Reversed- 
phase HPLC on a semipreparative C18 (ODP) column was repeated 
25 times. Active fractions were pooled and subjected to reversed- 
phase HPLC on an analytical  C2/C18 column (SuperPac  TM Pep-S, 
4  x  250 mm, 5/zm particles; Pharmacia LKB, Uppsala, Sweden) 
at neutral pH.  For peak a obtained in the first  round of HPLC 
analysis on the C18 (ODP) column (see Fig. 2 in the Results sec- 
tion),  solvent A  was 25%  acetonitrile,  and  solvent B was 40% 
acetonitrile, with a gradient of 0-100% B over 30 rain. For peak 
b obtained on the C18 (ODP) column, solvent A was water, and 
solvent B was 50% acetonitrile, with a gradient of 0-100% B over 
30 min followed by isocratic elution with 100% B for 10 rain. Frac- 
tions (1.0 ml) collected at 1 rain intervals were assayed for sensiti- 
zation activity as described  above. Active fractions were pooled and 
that of peak a but not peak b was subjected to gel-filtration  (Protein- 
Pak  TM 60 column, 7.8  ￿  300 mm, 10 #m particles; Waters Mil- 
lipore) and then reversed-phase  HPLC on a C2/C18 column under 
acidic conditions.  For peak a, solvent A and B were 25 and 40% 
acetonitrile, respectively,  containing 0.1% TFA. The gradient was 
0-100%  B over 60 min. For peak b,  solvent A was 0.1%  TFA, 
and solvent B was 50% acetonitrile, containing 0.1% TFA. The 
gradient was 0-100% B for 30 min followed by isocratic elution 
with 100% B over 10 min. Fractions (250 and 100/~1) were col- 
lected at intervals of 0.25 and 0.1 min, respectively,  and tested for 
sensitizing activity. 
Acid Elution from Affinity-purified H-2L  ~.  Cells were lysed in a 
solution (lysis buffer) of 0.5% NP-40, 10 mM Tris-HC1 (pH 7.5), 
0.2 mM p-amidinophenyl (pA)-PMSF, 5 mM EDTA, 5/lg/ml pep- 
statin A, and 5/~g/ml aprotinin. The supernatant obtained by cen- 
trifugation at  100,000 g  for 30 min was diluted to 0.1%  NP-40 
and loaded onto anti-L  d mAb (30-5-7)-coupled Afhgel-hydrazide 
(Bio-Rad Laboratories, Inc., Richmond,  CA).  The column was 
washed extensively with 60 vol of a solution of 10 mM Tris-HC1 
(pH 7.5),  0.2 mM pA-PMSF,  5 mM EDTA, and 150 mM NaC1, 
and then bound material was eluted with 0.1% TFA. The eluate 
was filtered  on a PLCC membrane with a cut off of m.w. 5,000 
(PLCC 5,000).  The filtrate was lyophilized and dissolved in 0.1% 
TFA for reversed-phase  HPLC. 
Generation of Con A  Blasts.  Spleen  cells (2  x  107) were cul- 
tured with Con A  at a concentration  of 5 #g/ml  for 3 d. 
Establishment and Maintenance of CTL  Clones.  CB6F1 spleen 
cells (5  x  107) from regressor mice were cultured with 5  x  106 
irradiated (100 Gy) RLo'I cells in tissue culture flasks (model 25100, 
Coming  Glass  Co.,  Coming,  NY) for 5 d  at 37~  under  5% 
CO2 in air. The culture medium was RPMI 1640 supplemented 
with 10% heat-inactivated FCS, 2 mM glutamine, 100 U of Peni- 
cillin/ml, 100 ~g of streptomycin/ml, and 50 #M 2-mercaptoeth- 
anol.  The harvested cells  (5  x  104) were maintained as a bulk 
CTL line by weekly restimulation with  10  s irradiated  (100 Gy) 
RLcYl  stimulator  cells  and  5  x  106 irradiated  (20 Gy) CB6F1 
splenic feeder cells in the presence of human recombinant IL-2 (rib2) 
(Takeda Chemical Industries, Osaka, Japan) at a concentration of 
5 ng/ml in 24-well culture plates (76-033-05;  Flow Laboratories, 
McLean, VA). Similar cultures from different mice were used for 
cloning. Cells were diluted to 3-0.3 cells/well and stimulated with 
104 irradiated RLO'I cells and 106 irradiated CB6F1 splenic feeder 
cells in the presence of rlL-2 in 96-well culture plates (model 25860, 
Coming Glass Co.).  After 10-14  d,  the cytotoxicity of clonaUy 
1600  Leukemia  Antigen  Peptide Recognized by CTL growing cells was tested. Six clones were chosen and maintained 
by weekly stimulation  as described above. 
Cell-mediated  Cytotoxicity  Assay.  Tumor cells and Con A blasts 
were  labeled by  incubating  2  x  106  cells with  2  MBq  of 
Na251CrO4 (New England  Nuclear, Boston,  MA)  in 0.3 ml of 
medium for 1 h at 37~  under 5% CO2 in air. The cells were 
then washed and used as target cells. In direct assays, 104 labeled 
target cells (100 #1) were incubated with the effector cell suspen- 
sion (100/A).  In antibody blocking assays, serially diluted mAb 
(100/A) was added to the culture of effector cells (50 #1) and la- 
beled target cells (50/A). In competitive inhibition  assays, unla- 
beled inhibitor cells (50/A) with or without sensitization by the 
peptide-containing HPLC fraction were added at different ratios 
to  104 SlCr-labeled RLO'I  target  cells (100 /A), and  then  the 
effector cells (50/~1) were added. In sensitization assays, 5 -10/A 
of HPLC fractions or peptide solution in 100 #1 of medium were 
added to 104 SlCr-labeled target cells (50/A) and incubated for 60 
min at room temperature before adding effector cells (50/A). After 
incubation for 4 h at 37aC under 5% CO2 in air, the superna- 
tants (100/zl) were removed and their radioactivity was measured. 
The percentage of  specific  lysis  was calculated  by the following equa- 
tion: [(a-b)/(c-b)]  x  100, where a is the radioactivity in the su- 
pernatant of target cells mixed with effector ceils, b is that in the 
supernatant of target cells incubated alone, and c is that in the su- 
pernatant  after lysis of target cells with 1% NP-40. 
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Figaare  1.  Direct  cytotoxicity  (.4) and antibody  blocking (B) of anti- 
RLO'I CTL in 4-h slCr-release  assay. The effector/target  cell ratios in B 
were 10 with bulk RLCrl CTL and 5 with clone 33. The bulk and all 
six cloned  CTL lines tested gave essentially similar results. NMS, normal 
mouse serum, 
Results 
Generation of Bulk  and  Cloned CTL  Lines Specific for 
RLCYl.  Inoculation of 106 RLcYl cells  into  the back of 
CB6F1  mice results in formation of a tumor and then its 
regression (11). When spleen ceils obtained from mice after 
tumor regression were cultured with irradiated (100 Gy) RLo'I 
ceils, cytotoxicity against the RLCrl cells was generated in 
5 d  (12).  The culture was maintained as a bulk CTL line 
by weekly repeated stimulation with 105 irradiated (100 Gy) 
RLO'I cells and 5  x  106 irradiated (20 Gy) CB6F1  splenic 
feeder cells in the presence of rlL-2 in 24-well culture plates. 
A culture from different mice was used for cloning. The cells 
were diluted to 3-0.3 cells/well and stimulated with 104 ir- 
radiated RLcyl ceils and 106 irradiated CB6F1 splenic feeder 
ceils in the presence of rlL-2 in 96-well culture plates. After 
culture for 10-14 d, the cytotoxicity of clonally growing cells 
was tested using half the culture. The other half was main- 
tained as a clone by repeated stimulation as described above. 
We established six cloned CTL lines: clone 12,  14, 31, 33, 
44,  and  103. 
The cytotoxicities of all the CTL lines against 1KLCYl  were 
eliminated by anti-Thy-l.2 mAb and anti-Lyt-2.2 (CD8) mAb, 
but not anti-L3T4 (CD4) mAb and complement, and were 
blocked by anti-CD3E mAb (125-2Cll), anti-TCR-fl mAb 
(H57-597), and anti-Lyt-2.2 (CD8) mAb, but not anti-TC1k-~ 
mAb (3A10) or anti-L3T4 (CD4) mAb in the absence of ex- 
ogenously added complement. 
The direct cytotoxicities of the bulk and the six cloned 
CTL lines were essentially similar. All the CTL lines showed 
cytotoxicity against IKLO'I, but not RLcY4, RLQ8, BALB- 
IKVA, C,  D,  P815,  or normal  splenic Con A  blasts  from 
BALB/c, C57BL/6, C3H, and (BALB/c x  B6)Ft mice. The 
results of a typical experiment are shown in Fig.  1 A. 
L d Restriction for Specific CTL  To Recognize RLO'I An- 
tigen.  The H-2 restriction molecule for specific CTL to recog- 
nize RLCYl antigen was determined by antibody blocking 
experiments. The cytotoxicities of the bulk and six cloned 
CTL lines were all blocked by anti-L  d mAb (30-5-7), but 
not by anti-K  a mAb (KD40), anti-IA  d mAb (MK-D6), anti- 
IE  k,a mAb (ISCR3), or anti-D  a mAb (DD98).  The results 
of a typical experiment are shown in Fig.  1 B. 
Fractionation of Acid Extract from  Whole RLcrl  Cells by 
Reversed-phase HPLC.  A  sample of 2.5  x  10  ll RLcYl as- 
cites cells from 250 BALB/c mice was homogenized with 
0.1% TFA. The homogenate was centrifuged at 100,000 g 
for 30 rain, and materials of <5,000 daltons were obtained 
by filtering the supernatant on a molecular cut-offmembrane 
and were separated by reversed-phase HPLC on a semiprepara- 
live C18 (ODP) column at an elution rate of 2 ml/min with 
an increasing concentration of acetonitrile. Each HPLC frac- 
tion (5 #1) was incubated with 51Cr-labeled P815 target and 
cytotoxicity by RLo'I CTL was determined. As shown in 
Fig. 2 A, sensitization activity was observed in two fractions, 
peaks a and b,  with elution times of 23 and 26 min.  The 
sensitization activities of the peaks a and b  fractions were 
observed with the bulk and all six cloned CTL lines.  The 
results of a typical experiment are shown in Fig.  2 B. 
Antibody blocking of sensitization of P815 with the ac- 
tive fractions was investigated. In these experiments, an ac- 
tive  fraction  and  antibody  were  present  in  the  culture 
throughout the assay. Sensitization was blocked by addition 
of anti-L  a mAb, but not anti-K  d mAb, anti-IA a mAb, anti- 
IE  k,a mAb, or anti-D  a mAb. Results were essentially  similar 
with the bulk and all six cloned CTL lines (data not shown). 
Competitive Inhibition of RLo'l  Cytotoxicity by P815 Cells 
Sensitized with  Active  Fractions.  P815  cells sensitized with active 
fractions were used as inhibitors of RLCYl cytotoxicity  in cam- 
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Figure  2.  Reversed-phase  HPLC  on  a  semipreparative  C18  (ODP) 
column with a 1%/min acetonitrile  gradient and sensitization  activity of 
each fraction  in 4-h slCr-release assay (A).  Samples of 5 #1 of each frac- 
tion collected in a volume of 2 ml/min were added to slCr-labeled P815 
target.  The effector cells used were the bulk RLcyl CTL. Active fractions 
eluted in 23 rain (peak a) and 26 min (peak b) were serially diluted  and 
tested for sensitization activity (B). Essentially similar sensitization activity 
was observed  with the bulk and all six cloned CTL lines  tested. 
petitive inhibition assays. P815 cells sensitized with either the 
peaks a or b  fraction inhibited the RLcYl cytotoxicities of 
the bulk and the six cloned CTL lines.  The results of a typ- 
ical  experiment  are shown in  Fig.  3. 
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Figure  3.  Competitive inhibition assays. Unlabeled  inhibitor cells (50 
#1) were serially diluted and added to 104 51Cr-labeled RLO'I target cells 
(100 #1). Effector cells were then added. Cytotoxicity was determined  by 
4-h slCr-release assay. The effector/target  cell ratio was 5 with bulk CTL 
and 3 with clone 33. 
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Figure  4.  Sensitization activity of fractions separated by reversed-phase 
HPLC on a semipreparative C18 (ODP) column of an acid extract from 
whole cells (.,t) and an acid eluate from affinity-purified L  a molecules (B). 
cules from RLCYl.  A  sample of 4.0  x  101~  RLO'I  ascites 
cells from 40 BALB/c mice was suspended in lysis buffer con- 
taining 0.5%  NP-40 and incubated for 30 rain at 4~  with 
shaking. The cell lysate obtained by ultracentrifugation was 
loaded onto an anti-L  d mAb-binding affinity column and the 
eluate in 0.1% TFA was collected.  Materials of<5,000 daltons 
were obtained by filtering the eluate on a molecular cut-off 
membrane and were separated  by reversed-phase  HPLC on 
a semipreparative C18 column as described above. Each frac- 
tion (20/~1) was tested for sensitization activity. Fraction 23, 
but not fraction 26,  showed sensitization  activity (Fig.  4). 
Further Purification of CTL-recognizing Peptides.  For puri- 
fication of active peptides,  fractions in peaks a and b  sepa- 
rated on a semipreparative C18 (ODP) column were further 
separated by reversed-phase  HPLC on an analytical C2/C18 
column at neutral pH and collected in volumes of 1 ml/min. 
As shown in Fig. 5, the active peptide in peak a was eluted 
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Figure 5.  Reversed-phase HPLC fractions of peak a (A) and b (B) on 
the semipreparative C18 (ODP) column shown in Fig. 2 A were further 
separated by reversed-phase HPLC on an analytical C2/C18 column with 
an acetonitrile  gradient  of 0.5  (A) or 1.66%  (/3) per rain at neutral  pH. 
Arrows indicate  active fractions. 
1602  Leukemia Antigen Peptide  Recognized by CTL in fraction  12, and the active peptide in peak b  was eluted 
in fraction 30.  Fraction 12 derived from peak a at a neutral 
pH was purified by repeated HPLC  (seven times)  and was 
subjected to gel filtration. The active fraction was then sepa- 
rated by reversed-phase  HPLC in acidic conditions on an an- 
alytical C2/C18 column in fractions of 250/~1/15 s and each 
fraction was tested for sensitization activity (Fig. 6 A). Frac- 
tions with peak sensitization activity were denoted as a'. Frac- 
tion 30 from peak b in neutral pH conditions was purified 
by repeated HPLC (six times) and was separated by reversed- 
phase HPLC  in acidic conditions  on an analytical  C2/C18 
column and collected in fractions of 100/xl/6 s and each frac- 
tion was similarly tested for sensitization activity (Fig. 6 B). 
The fractions with peak sensitization activity were denoted 
as b'. 
A mino Acid Sequencing by Edman Degradation.  The amino 
acid sequences of peptides in active fractions of peaks a' and 
b' were analyzed by automated Edman degradation. The oc- 
tamer peptide  IPGLPLSL was identified  in  the fraction of 
peak a', and the decamer peptide SIIPGLPLSL was identified 
in  the fraction of peak b'. 
Characterization of Synthetic Peptides.  Peptides IPGLPLSL 
and SIIPGLPLSL were synthesized and their sensitization ac- 
tivities were investigated.  As shown in Fig.  7 A,  sensitiza- 
tion on P815 and T1.1.1 (La-transfected  L cell line) cells was 
observed at concentrations as low as 1-100 nM with the bulk 
and cloned RLO'I CTL lines.  The sensitization  activity of 
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Figure  6.  Fraction 12 shown in Fig. 5 A  derived from peak a in Fig. 
2 A was separated by reversed-phase HPLC on an analytical C2/C18 column 
in 0.1% TFA with an acetonitrile  gradient  of 0.25%/rain and fractions 
in a volume of 250 #1/15  s were collected  (A).  Fraction 30 in Fig. 5 B 
derived from peak b in Fig. 2 A  was separated by reversed-phase HPLC 
on an analytical C2/C18 column in 0.1% TFA with an acetonitrile gra- 
dient of 1.66%/min and fractions of 100/xl per 6 s were collected  (B). 
The materials in fractions that showed maximal sensitization  (a' and b') 
as well as adjacent fractions were sequenced by automated Edman degra- 
dation. 
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Figure  7.  Sensitization  (A) and reversed-phase HPLC analysis (B) of 
synthetic peptides pRL1. (A) Cytotoxicity by RLo'I CTL of T1.1.1  (L  d- 
transfected L cell line) ( ...... ), T4.8.3 (- - -) (Dd-transfected L cell line), 
and P815 (  ) target cells sensitized  with synthetic  pRL1 peptides  ex- 
amined by 4-h sICr-release assay. The amino acid sequences of pRLla and 
b are IPGLPLSL and SIIPGLPLSL, respectively. Target cells were prein- 
cubated with the peptides  for 1 h  at room temperature before addition 
of the effector cells. Effector/target  cell ratios were 5 for the bulk CTL, 
and 3 for clone 33.  (B) Synthetic pRLla and b subjected independently 
to reversed-phase HPLC on a semipreparadve  C18 (ODP) column as shown 
in Fig. 2. The elution times of pRLla and pRLlb were 23 rain and 26 
rain,  respectively. 
SIIPGLPLSL was slightly less than that of IPGLPLSL. Anal- 
),sis by reversed-phase HPLC on a semipreparative C18 column 
revealed  that the peptide IPGLPLSL was eluted in 23 min, 
and the peptide SIIPGLPLSL was eluted in 26 min (Fig.  7 
B).  Peptides  IPGLPLSL and SIIPGLPLSL were denoted  as 
pRLla  and b,  respectively. 
Amino  Acid Sequence Homology.  Amino  acid  sequence 
homology was investigated.  Octamer peptide pRLla (IPG- 
LPLSL) was identical to amino acid residues 271-278 of the 
product of v-Akt (16, 26) (Table 1). Decamer peptide pRLlb 
(SIIPGLPLSL) differs from Akt in having an NH2-terminal 
Ser residue in place of the Ile residue at position 269 ofv-Akt. 
Table  1.  Amino Acid Sequences of pRL1  and Akt 
pRLla  I  PGLPLSL 
pRLlb  S  I  I  PGLPLSL 
Akt  REETL  I  I  I  PGLPLSLGATDT 
The amino acid sequence of Akt corresponds to residues 264-283 of v-Akt 
in which the nucleotide  sequence is in 5' untranslated region of c-akt next 
to  the ATG codon  (26). 
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sensitization activity. Results showed that its sensitization 
activity was as high as that of pRLlb (SIIPGLPLSL) (data 
not shown). 
Discussion 
CD8 § CTL recognize a peptide fragment in association 
with a MHC class I molecule (27). The amino acid sequences 
of naturally occurring peptides recognized by CTL have been 
determined by two alternative approaches. One is determi- 
nation of amino acid sequences based on information on the 
nucleotide sequences that are responsible for susceptibility 
of target cells to lysis by CTL. Boon's group identified sev- 
eral genes (28) identified several genes encoding tumor rejec- 
tion antigens in mice and humans. Mouse mastocytoma P815 
expresses several distinct antigens that are recognized by syn- 
geneic (DBA/2) CTL. By transfecting a cosmid library de- 
rived from P815 cells into a variant that did not express P815A 
and P815B antigens and by packaging directly the DNA of 
a transfectant with )~phage extracts, they isolated gene P1A, 
which directs the expression of  both antigens (29). One variant 
that had lost only antigen A displayed a point mutation. Syn- 
thetic peptides that corresponded to the normal sequence lo- 
cated in the region of this point mutation sensitized target 
cells (30). The PIA gene in this cell line is not mutated, but 
the gene is not expressed normally. They extended their anal- 
yses to human tumors and identified the MAGE gene family 
in a malignant melanoma. Nonapeptides encoded by MAGE-I 
and -3  genes are recognized in association with  HLA-A1 
(31-33).  Furthermore, they found that two nonapeptides en- 
coded by the tyrosinase gene are recognized in association 
with HLA-A2 on tumors by autologous CTL (34,  35). 
The other approach for determination of the amino acid 
sequences of naturally occurring peptides recognized by CTL 
involves  extraction of the peptides from MHC molecules, 
and their purification and direct sequencing. Peptides that 
sensitize targets to lysis by specific CTL can be extracted with 
acid from cells expressing appropriate class I molecules (36-38), 
and attempts have been made to sequence these peptides. There 
are several reports on determinations of their amino acid se- 
quences. Udaka et al. identified an octapeptide p2Ca (39) and 
a 16-met peptide p2Cb  (40)  that includes the entire p2Ca 
from BALB/c spleen cells that are recognized by allogeneic 
La-specific 2C CTL.  2C CTL was established by immuni- 
zation of BALB.B  (H-2  b) mice with H-2  a cells,  p2Ca and 
b  peptides  are  derived  from  mouse  2-oxoglutarate  de- 
hydrogenase. Henderson et al. (41) reported a nonamer pep- 
tide 1049 recognized by xenogeneic HLA-A2.1-specific mu- 
rine CTL by mass spectrometry. Recently, Cox et al.  (42) 
demonstrated that peptide 946 associated with the HLA-A2.1 
molecule on melanomas recognized by CTL from different 
patients by mass spectrometry. Mandelboim et al. (43) reported 
an octapeptide on murine Lewis lung carcinoma (3LL) rec- 
ognized by specific CTL. This peptide originates from mu- 
tated connexin 37. In this study, we identified a pRL1 pep- 
tide on BALB/c radiation-induced leukemia RLcYl that is 
recognized by specific CTL and showed that it is derived from 
the akt oncogene. 
An acid extract of RLo'I cells was fractionated by reversed- 
phase HPLC on a semipreparative C18  column. Fractions 
eluted in 23 rain (peak a) and 26 min (peak b) showed sen- 
sitization activity on P815 cells for the bulk and all six cloned 
RLCel specific CTL lines. Antibody blocking indicated that 
recognition of the P815 target sensitized with either the peak 
a or b fraction by RLcYl CTL was restricted to L a like that 
of the RLcYl target (data not shown). Competitive inhibi- 
tion assays showed that the RLo'I cytotoxicities of the bulk 
and cloned CTL lines were inhibited by P815 target cells sen- 
sitized with either the peak a or b fraction as efficiently as 
by unlabeled RLcYl. These findings suggest that the pep- 
tides in the peak a and b fractions bind to the L  a molecule 
and create a common antigenic epitope that is dominantly 
recognized by anti-RLcYl CTL. Amino acid sequence anal- 
),sis by Edman degradation revealed an octamer peptide pRLla 
(IPGLPLSL) in the peak a fraction and a decamer peptide 
pRLlb (SIIPGLPLSL)  in the peak b fraction. The sensitiza- 
tion  activities  of  these  peptides  on  P815 and  the  L d- 
transfected L cell line T1.1.1 were observed at concentrations 
as low as 1-100 nM with the bulk and all six cloned CTL 
lines tested. In a 4-h cytotoxicity assay, sensitization activity 
of the pRLla  peptide  was  observed in  medium with  or 
without serum, whereas that of the pRLlb peptide was di- 
minished in medium without serum (data not shown). These 
findings suggest conversion of pRLlb  to pRLla by pepti- 
dases present in FCS. There are several reports of generation 
of optimal sized peptides from larger fragments by specific 
extracellular peptidases in cells sensitized with exogenous pep- 
tides to class/-restricted cytotoxic T cells. Exogenously added 
11-met peptide 147-158/R-  of the influenza virus nucleo- 
protein (form altered at residues 147-158,  in which the Arg 
at position 156 is deleted) was presented resulting from removal 
of the COOH-terminal  Thr and Gly by the angiotensin- 
converting enzyme (ACE) present in FCS (44). Cleavage by 
ACE was also observed with the HIV-1 gp160-derived 15- 
mer peptide p18 presented by H-2D d (45). Furthermore, re- 
cently, it has been shown that the sensitization activity of 
the naturally occurring 16-met peptide p2Cb (see above) ap- 
pears to be due to cleavage of eight NH2-terminal residues 
in medium containing serum during the course of cytotox- 
icity assay (40). 
There is a report that in a whole cell extract of minor H 
antigen H-4b-positive cells, H-4-specific Kb-restricted CTL 
B21W9 recognized two HPLC fractions (38).  But in pep- 
tide mixtures eluted from purified K b molecules of the same 
cells, CTL recognize only one. In our study, using an acid 
extract from affinity-purified L a molecules of RLo'I,  the 
reversed-phase HPLC fraction eluted in 23 min but not that 
eluted in 26 min from a semipreparative C18  column had 
sensitization activity. This finding suggests that the octamer 
peptide pRLla (IPGLPLSL) is the CTL-recognizing peptide 
that is presented by L a molecules on the RLO'I cell surface 
and that it is generated from the pRLlb (SIIPGPLPSL) pep- 
tide by removal of Ser  and  lie from  the NHz  terminus. 
Thus,  pRLlb  could be an intermediate in  the processing 
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class I molecules. Udaka et al.  (40) showed that incubation 
of p2Cb with purified proteasomes resulted in a new peak 
of material with sensitizing activity that had the same reten- 
tion  time as octamer peptide p2Ca,  which was concluded 
previously to be the active peptide recognized by 2C cells. 
The findings suggest that p2Cb is a precursor of p2Ca, the 
final product in the processing pathway. An alternative pos- 
sibility is that the binding affinity of pRLlb to the L d mol- 
ecule is much lower than that of pRLla and, therefore, resulted 
in poor recovery of the peptide on elution from affinity-purified 
L a molecules. 
It is usually difficult to determine the sequence of a CTL- 
recognizing  peptide  directly  because of limitation  in  the 
amount of peptide available. A sample of 5-10 nmol of starting 
material would be required for several rounds of purification 
for obtaining a single peak that can be assumed to contain 
one or two peptides (46), although only 150-200 target pep- 
tides presented on a class I molecule seem to be required for 
target cell lysis when recognized by CTL (47). In the present 
study, in three sequential purification procedures by HPLC, 
the final yield was ~5%.  Since the yield from 2.5  x  1011 
cells was m40 pmol, the number ofpRL1 peptides on a single 
RLcYl cell was calculated to be *2,000. 
Oncogenes are often mutated or overexpressed in malig- 
nant  cells  (48).  C57BL/10 mice immunized  with vaccinia 
virus expressing either the mutated or nonmutated ms gene 
were found to generate CTL specific for the peptides used 
for immunization (49). BALB/c mice immunized with spleen 
cells pulsed with mutated p53 peptide generated specific CTL 
(50).  Furthermore,  CTL were generated in B6 spleen cells 
by primary in vitro stimulation with mutated ras peptide (51). 
The present finding that  the akt oncogene codes for pRL1 
supports the findings  that  the oncogene product could be 
the epitope of a tumor rejection antigen that can be recog- 
nized by CTL. The v-akt gene was found in a defective clone 
of the AKT8 virus, which was an acute transforming retrovirus 
isolated from a AKT T  cell lymphoma,  and was generated 
by the in frame fusion of gag and c-akt. The protein encoded 
by v-akt is a tripartite gag-X-c-akt fusion protein of which 
X  is a 21-amino acid peptide derived primarily from the 5' 
untranslated  region of the gene (26).  Acquisition of trans- 
forming properties by v-akt appeared to be due to the addi- 
tion  of the  gag-X  sequences  at  the  NH2  terminus  (52). 
Myristylation and membrane association of v-Akt are likely 
to be critical for the oncogenic properties. C-akt mRNA is 
expressed in all tissues tested (26). The pRL1 peptides shown 
in the present study correspond to the sequence in the 5' un- 
translated  region  of c-akt,  pR.Lla is derived from residues 
271-278 and ptLLlb from residues 269-278 of v-Akt. The 
amino acid residue Ile at position 269 in v-Akt is replaced 
by Set in pRLlb. Since the decamer peptide IIIPGLPLSL also 
showed sensitization  activity, Set at  the NH2 terminus  of 
pRLlb is not responsible for sensitivity to cleavage by dipep- 
tidase. 
In addition to the RLCYl unique antigen demonstrated in 
this study, a number of unique antigens recognized by specific 
CTL have been identified in other leukemias. Whether  the 
unique antigen peptides on these leukemias are also derived 
from the akt oncogene or from other genes remains to be seen. 
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